Lumida
/SLSN
⌘K
Solesence Inc

Solesence Inc

SLSN
$0.81USD↓-2.59%-0.02 today

MARKET CAP

57.1M

P/E (TTM)

80.9x

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$5

AI Summary

Stalk
StalkMedium

Following a post-capitulation volatility contraction and lower wick absorption since mid-July, price is stabilizing at the capitulation low. With Mean Reversion eligibility and a flattened EMA regime, the medium-term bias is Bullish, but short-term timing remains Neutral awaiting evidence of support holding. Stalk around the absorption-support zone for a potential mean-reversion bounce.

  • ↑Order backlog at $64.9M implies robust revenue pipeline and underpins management’s double-digit growth target.
  • ↑Management forecasts ~$35M in H2 2026 sales, marking the strongest half-year in company history.
  • ↓Q2 2026 revenue dropped 25% YoY to $15.3M, eroding top-line momentum.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Solesence, Inc. (NASDAQ: SLSN) specializes in the development and manufacturing of mineral-based skin health and beauty products. The company is positioned as a leader in the beauty and personal care industry, leveraging a comprehensive patent portfolio to drive innovation and establish strong strategic partnerships with brand names in skincare and cosmetics. The firm focuses on catering to the rising consumer demand for SPF-infused products amid shifting market trends that emphasize health and wellness in beauty solutions.

Bull says

  • ↑Order backlog at $64.9M implies robust revenue pipeline and underpins management’s double-digit growth target.
  • ↑Management forecasts ~$35M in H2 2026 sales, marking the strongest half-year in company history.
  • ↑Strategic deals account for 30–60% of partner revenues, fueling innovation and market share gains.
  • ↑‘Transform and Transcend’ initiative is improving production cost efficiency and boosting margins.
  • ↑High qualitative score and positive earnings revisions suggest overlooked value and upside potential.
  • ↑Rising consumer demand for SPF-infused mineral products aligns with health-conscious beauty trends.

Bear says

  • ↓Q2 2026 revenue dropped 25% YoY to $15.3M, eroding top-line momentum.
  • ↓Net loss of $158K and gross margin down to 31% signal ongoing profitability challenges.
  • ↓High leverage and a 45% jump in operating expenses heighten financial risk.
  • ↓Heavy reliance on key brand partners exposes revenue to their performance volatility.
  • ↓Negative earnings yield and weak momentum factors indicate potential for further stock declines.
  • ↓Past restatements and transparency issues undermine investor confidence.

Investment themes with SLSN

Specialty Chemical↑ +2.23%

ECL · ALB · IFF

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 09-03-2026neutral

Transcript signals

Bull points

  • I'm pleased to report we delivered a strong second quarter, both commercially and operationally.
  • This exceptional performance has not only solidified our customer relationships, but also positioned us as well for repeat orders.
  • we uplisted our common shares at the NASDAQ, a major milestone for Celescence and our valued shareholders.

Bear points

  • Looking ahead, we anticipate moderating demand levels based on softer macroeconomic conditions.
  • Looking ahead, we anticipate moderating demand levels based on softer macroeconomic conditions.
  • we anticipate demand to slow in the second half of 2025 as tariffs affect global purchasing decisions and consumer buying habits.
Read full transcript analysis ›